Get the Stockscreener App
43.36
1.88%
-0.83
After Hours:
43.36
Merus N V stock is traded at $43.36, with a volume of 412.65K.
It is down -1.88% in the last 24 hours and up +13.78% over the past month.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$44.19
Open:
$44.23
24h Volume:
412.65K
Relative Volume:
0.61
Market Cap:
$3.13B
Revenue:
$35.93M
Net Income/Loss:
$-244.56M
P/E Ratio:
-10.98
EPS:
-3.95
Net Cash Flow:
$-157.31M
1W Performance:
-4.24%
1M Performance:
+13.78%
6M Performance:
-16.21%
1Y Performance:
-10.34%
1-Day Range:
$43.04
$45.12
1-Week Range:
$43.04
$46.36
52-Week Range:
$33.19
$61.61
Merus N V Stock (MRUS) Company Profile
Name
Merus N V
Sector
Industry
Phone
31 030 253 8800
Address
YALELAAN 62, 3584 CM UTRECHT
Compare MRUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
43.36 | 3.13B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Piper Sandler | Overweight |
| Feb-07-25 | Initiated | Wells Fargo | Overweight |
| Nov-21-24 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Mar-28-24 | Initiated | Truist | Buy |
| Mar-04-24 | Reiterated | Needham | Buy |
| Nov-02-23 | Initiated | Canaccord Genuity | Buy |
| Aug-21-23 | Initiated | TD Cowen | Outperform |
| Aug-02-22 | Initiated | Stifel | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Needham | Buy |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Jun-07-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-08-21 | Initiated | William Blair | Outperform |
| Mar-16-21 | Initiated | SVB Leerink | Outperform |
| Jun-26-20 | Initiated | H.C. Wainwright | Buy |
| May-27-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-20-19 | Resumed | Guggenheim | Buy |
| Jun-28-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Resumed | Guggenheim | Buy |
| Apr-03-19 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Mar-21-17 | Downgrade | Citigroup | Buy → Neutral |
| Dec-22-16 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-16 | Downgrade | Citigroup | Buy → Neutral |
| Jun-13-16 | Initiated | Citigroup | Buy |
| Jun-13-16 | Initiated | Guggenheim | Buy |
| Jun-13-16 | Initiated | Wedbush | Outperform |
View All
Merus N V Stock (MRUS) Latest News
(MRUS) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Was Merus N.V (MRUS)’s session last reading good? - uspostnews.com
Merus (NASDAQ:MRUS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Q1 Earnings Forecast for Merus Issued By Leerink Partnrs - Defense World
Investor Network: Merus N.V. to Host Earnings Call - ACCESS Newswire
FY2027 Earnings Forecast for Merus Issued By Leerink Partnrs - Defense World
Merus (NASDAQ:MRUS) Position Lifted by Geode Capital Management LLC - Defense World
William Blair Reiterates Outperform Rating for Merus (NASDAQ:MRUS) - Defense World
Market Watch Highlights: Merus N.V (MRUS) Ends on an Upturn Note at 45.28 - DWinneX
Russell Investments Group Ltd. Decreases Stock Holdings in Merus (NASDAQ:MRUS) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Merus N.V (MRUS) Is Worth Accumulating At Current Levels - Stocksregister
Daily Progress: Merus N.V (MRUS) Drop -3.19, Closing at 41.83 - DWinneX
MRUS Stock Sees Decline of Approximately -3.22% in Last Five Days - knoxdaily.com
Merus N.V’s Banking’s 100-Day Moving Average at 43.17: Will the Stock Break Through? - investchronicle.com
Merus annonce l’acceptation de son résumé pour présentation au congrès annuel 2025 de l’ASCO® - GlobeNewswire Inc.
A stock that deserves closer examination: Merus N.V (MRUS) - uspostnews.com
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting - The Manila Times
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting | MRUS Stock News - GuruFocus
Merus N.V. Announces Interim Clinical Data for Petosemtamab with Pembrolizumab in PD-L1+ r/m HNSCC to be Presented at 2025 ASCO® Annual Meeting - Nasdaq
Breakthrough Cancer Drug Outperforms Standard Treatment: Phase 2 Trial Shows Superior Survival Rates - Stock Titan
ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals | Libero Quotidiano.it - Libero Quotidiano
Is Merus (NASDAQ:MRUS) the Best High Short Interest Stock to Buy Now? - Yahoo
10 Best High Short Interest Stocks to Buy Now - Insider Monkey
Merus N.V (NASDAQ: MRUS): Getting A Free Pass? - stocksregister.com
Merus’ (MRUS) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Raymond James Financial Inc. Invests $347,000 in Merus (NASDAQ:MRUS) - Defense World
Merus: Riding The Bispecific Wave In Oncology (NASDAQ:MRUS) - Seeking Alpha
KLP Kapitalforvaltning AS Purchases New Holdings in Merus (NASDAQ:MRUS) - Defense World
Merus stock touches 52-week low at $37.76 amid market challenges By Investing.com - Investing.com South Africa
Merus stock touches 52-week low at $37.76 amid market challenges - Investing.com Australia
HighTower Advisors LLC Has $337,000 Position in Merus (NASDAQ:MRUS) - Defense World
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
How To Trade (MRUS) - news.stocktradersdaily.com
Leading Biotech Merus Showcases Next-Gen Antibody Technologies at Major Healthcare Conference - Stock Titan
Merus (NASDAQ:MRUS) Shares Purchased by Teacher Retirement System of Texas - Defense World
Guggenheim Reiterates “Buy” Rating for Merus (NASDAQ:MRUS) - Defense World
Swiss National Bank Purchases 8,300 Shares of Merus (NASDAQ:MRUS) - Defense World
Merus VP controller Shuman sells $193,990 in common shares By Investing.com - Investing.com India
Merus VP controller Shuman sells $193,990 in common shares - Investing.com
Bank of New York Mellon Corp Sells 1,248 Shares of Merus (NASDAQ:MRUS) - Defense World
Merus (MRUS) Gets a Buy from Citi - The Globe and Mail
US Bancorp DE Lowers Holdings in Merus (NASDAQ:MRUS) - Defense World
Merus (NASDAQ:MRUS) Given “Buy” Rating at Guggenheim - Defense World
Merus (NASDAQ:MRUS) Given Average Recommendation of “Buy” by Brokerages - Defense World
Merus (NASDAQ:MRUS) Given New $70.00 Price Target at Bank of America - Defense World
Why Merus Shares Are Facing Pressure Today - TipRanks
Merus N V Stock (MRUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):